Search Results

The Varelisa ReCombi ANA Profile EIA kit is designed for the qualitative determination of eight antinuclear antibodies in human serum or plasma to aid in the diagnosis of SLE (systemic lupus erythematosus), scleroderma (progressive systemic sclerosis and CREST syndrome), MCTD (mixed connective tissue disease), SS (Sjögren's syndrome) and polymyositis/dermatomyositis. The Varelisa ReCombi ANA Profile individually detects antibodies against dsDNA, U1 RNP (RNP 70 kDa,A,C), SmD, SS-A/Ro(52 kDa, 60 kDa), SS-B/La, Scl-70, CENP-B and Jo-1.

The new device is an enzyme-linked immunosorbent assay (ELISA) using microtiter plates as the solid phase. Plate wells each coated with 1 of 8 different ANA antigens are included to allow corresponding antibodies in the patient samples react with the immobilized antigens. The conjugate is rabbit anti-human IgG horseradish peroxidase (HRP), which uses 3, 3'5, 5' tetramethylbenzidine dihydrochloride (TMB) as substrate. The kit contains a calibrator and a negative control. The kit also contains sample diluent, wash buffer concentrate and stop solution.

Here's an analysis of the acceptance criteria and study information based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The provided text does not explicitly state numerical acceptance criteria for the Varelisa ReCombi ANA Profile. Instead, it focuses on demonstrating "substantial equivalence" to predicate devices through comparability studies. Therefore, reported device performance is framed in terms of agreement with predicate devices and established reference standards.

• results obtained within a comparison study analyzing positive, equivocal, and negative sera.
• results obtained for international reference sera.
• results obtained for samples from apparently healthy subjects (normal population). |

2. Sample Size Used for the Test Set and Data Provenance

The document mentions "a comparison study analyzing positive, equivocal and negative sera" and "samples from apparently healthy subjects (normal population)" but does not specify the exact sample size for the test set or the country of origin of the data. It can be inferred that the data is retrospective as it refers to a "comparison study" and "available data," suggesting pre-collected samples.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

The document does not specify the number of experts used or their qualifications for establishing ground truth. The nature of the device (an immunoassay for antibody detection) suggests that ground truth would likely be established through clinical diagnosis of autoimmune diseases or by established reference methods for antibody detection, rather than expert interpretation of images or complex data.

4. Adjudication Method for the Test Set

The document does not provide information on any adjudication method used for the test set.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

A Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done. This type of study is more relevant for diagnostic devices that rely on human interpretation of images or complex data, where the AI might assist a reader. The Varelisa ReCombi ANA Profile is an automated immunoassay where the output is a qualitative determination (positive/negative) based on optical density readings, not a human interpretation task.

6. Standalone (Algorithm Only) Performance Study

Yes, a standalone performance study was done implicitly. The entire evaluation described for the Varelisa ReCombi ANA Profile relates to its performance as a standalone assay, comparing its results directly to predicate devices and reference materials. The device is the algorithm, producing results without human-in-the-loop assistance for interpretation of the test itself.

7. Type of Ground Truth Used

The ground truth used appears to be a composite of:

• Clinical Diagnosis: The intended use states the kit "aids in the diagnosis of SLE... scleroderma... MCTD... SS and polymyositis/dermatomyositis," implying that patient samples from individuals with confirmed diagnoses of these conditions would serve as ground truth for "positive" samples.
• Established Reference Materials: The study mentions "results obtained for international reference sera," indicating that recognized standard antibody preparations were used as ground truth.
• Predicate Device Results (as a gold standard proxy): A significant part of the study involves comparing the new device's results to those obtained with the predicate devices for positive, equivocal, and negative sera. This suggests the predicate device's performance served as a de-facto "ground truth" for demonstrating equivalence.
• Healthy Controls: "Samples from apparently healthy subjects (normal population)" were used to establish negative ground truth.

8. Sample Size for the Training Set

The document does not mention a training set or its sample size. This is typical for a traditional immunoassay device. "Training" in the context of an AI/ML device would refer to the data used to develop the algorithm. For this device, the "algorithm" is the biochemical assay itself and its reading protocol, not a machine learning model that learns from large datasets. The development process would involve optimization and validation runs rather than distinct "training" and "test" sets in the AI sense.

9. How the Ground Truth for the Training Set Was Established

As no training set is mentioned in the AI/ML context, this question is not applicable. The "ground truth" for the development of the assay would have been established through a combination of chemical and biological principles, known antibody-antigen reactions, and clinical validation against diagnosed patient samples and controls, rather than a specific "ground truth for a training set."

Ask a specific question about this device

The Varelisa ReCombi ANA Profile EIA kit is designed for the qualitative determination of eight antinuclear antibodies in human serum or plasma to aid in the diagnosis of systemic rheumatic diseases such as SLE (Systemic Lupus Erythematosus), Scleroderma (Progressive Systemic Sclerosis), MCTD (Mixed Connective Tissue Disease), SS (Sjögren's Syndrome) and Polymyositis/ Dermatomyositis. The Varelisa ReCombi ANA Profile individually detects antibodies against dsDNA, RNP(68 kDa, A, C), Sm(B,B',D) SS-A/Ro(52 kDa, 60 kDa), SS-B/La, Scl-70, Centromere and Jo-1.

The Varelisa ReCombi ANA Profile is an enzyme immunoassay for the individual qualitative determination of 8 antinuclear antibodies in serum or plasma.

Here's a breakdown of the acceptance criteria and study details based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria for substantial equivalence of the Varelisa ReCombi ANA Profile to its predicate devices specifically relate to a high degree of correlation in the results.

2. Sample Size and Data Provenance for the Test Set

• Sample Size for Test Set: 112 samples were used, including 20 apparently healthy blood donors.
• Data Provenance: Not explicitly stated (e.g., country of origin). The study is retrospective in the sense that existing samples (including "apparently healthy blood donors") were tested using both devices.

3. Number of Experts and Qualifications for Ground Truth

• This information is not provided in the given text. The ground truth for the comparison is the results obtained from the predicate devices, not an independent expert consensus on patient status.

4. Adjudication Method for the Test Set

• This information is not applicable as the comparison is directly between the results of the new device and the predicate devices. There's no mention of a human adjudication process for discrepancies.

5. Multi Reader Multi Case (MRMC) Comparative Effectiveness Study

• No, an MRMC comparative effectiveness study was not done. This study focuses on the performance of a diagnostic kit (an in-vitro diagnostic device) compared to predicate devices, not on the impact of a device on human readers' interpretive performance.

6. Standalone Performance Study

• Yes, a standalone study was done, in the sense that the Varelisa ReCombi ANA Profile was tested independently on the 112 samples and its results were then compared to those of the predicate devices. The performance metrics of 96% agreement (overall and individual parameter) are indicative of its standalone performance in relation to the predicate.

7. Type of Ground Truth Used

• The "ground truth" for this study was the results obtained from the predicate devices (Varelisa ANA Profile and Varelisa dsDNA Antibodies Assay). Additionally, the study used ANA Reference Sera CDC-1 to CDC-10 from the Centers of Disease Control and Prevention for which the "correct specificities" served as another form of ground truth.

8. Sample Size for the Training Set

• This information is not provided as this is an in-vitro diagnostic device and the "training set" concept (as usually applied to AI/machine learning) is not directly relevant here. The device's formulation and manufacturing would be based on internal development and validation, but not a "training set" in the computational sense.

9. How Ground Truth for Training Set Was Established

• This information is not applicable as there is no mention of a training set in the AI/machine learning context. The development of the Varelisa ReCombi ANA Profile would have involved rigorous R&D and internal validation to ensure its reagents and methodology accurately detect the target antibodies, but this isn't described in terms of a "training set" and "ground truth" as typically understood in AI studies.

Ask a specific question about this device